Literature DB >> 9752271

Improvement of the Cockcroft-Gault equation for predicting glomerular filtration in cancer patients.

L Martin1, E Chatelut, A Boneu, L Rostaing, C Roussilhes, O Caselles, P Canal.   

Abstract

In order to determine the morphological and biological covariables which better predict the glomerular filtration rate in cancer patients, we performed the present study in a population of 123 patients (78 men, 45 women) with various tumor types; 55 of these patients had previously received cisplatin, and 12 had undergone unilateral nephrectomy. The 51Cr-EDTA plasma concentration versus time data of 80 patients were analysed according to a population pharmacokinetic approach by using the Nonlinear Mixed Effects Model (Nonmem) program. The best fit for 51Cr-EDTA clearance estimation was given by the following formula: [formula: see text] (with ABW for actual body weight in kg, age in years, sex = 0 if male and sex = 1 if female, and Scr for serum creatinine in mumol/l). Actual body weight was the most predictive morphologic parameter, and the adjustment was not improved by taking into account the ideal body weight. The GFR of patients previously treated with cisplatin was 18% lower than that of untreated patients age for age. However, this covariable was not present in the final model because it was redundant with other covariables, likely Scr. The formula was then prospectively evaluated with the data of 43 other patients. The mean (+/- SD) ratio between GFR predicted according the Nonmem formula and the observed GFR was 0.95 +/- 0.23 which did not differ significantly from unity. Conversely, the mean ratio between creatinine clearance calculated according to the Cockcroft-Gault equation and the observed GFR (0.86 +/- 0.21) differed significantly from unity. This study shows that in cancer patients the formula to calculate GFR drawn from Nonmem analysis is more accurate than the Cockcroft-Gault equation. However, an accurate determination of GFR requires specific techniques as 51Cr-EDTA clearance investigation.

Entities:  

Mesh:

Year:  1998        PMID: 9752271

Source DB:  PubMed          Journal:  Bull Cancer        ISSN: 0007-4551            Impact factor:   1.276


  16 in total

Review 1.  Pharmacokinetically guided administration of chemotherapeutic agents.

Authors:  H J van den Bongard; R A Mathôt; J H Beijnen; J H Schellens
Journal:  Clin Pharmacokinet       Date:  2000-11       Impact factor: 6.447

Review 2.  Body surface area as a determinant of pharmacokinetics and drug dosing.

Authors:  M Sawyer; M J Ratain
Journal:  Invest New Drugs       Date:  2001-05       Impact factor: 3.850

Review 3.  Accurate measurement of individual glomerular filtration rate in cancer patients: an ongoing challenge.

Authors:  Karin Holweger; Carsten Bokemeyer; Hans-Peter Lipp
Journal:  J Cancer Res Clin Oncol       Date:  2005-10-20       Impact factor: 4.553

4.  Accuracy of GFR estimation by the Cockroft and Gault, MDRD, and Wright equations in Oncology patients with renal impairment.

Authors:  O O Faluyi; S P Masinghe; R L Hayward; S Clive
Journal:  Med Oncol       Date:  2011-02-01       Impact factor: 3.064

5.  Contribution of the MDRD equation and of cystatin C for renal function estimates in cancer patients.

Authors:  Sophie Séronie-Vivien; Stéphanie Toullec; Laurence Malard; Fabienne Thomas; Valérie Durrand; Etienne Chatelut
Journal:  Med Oncol       Date:  2006       Impact factor: 3.064

Review 6.  Guidelines for treatment of renal injury during cancer chemotherapy 2016.

Authors:  Shigeo Horie; Mototsugu Oya; Masaomi Nangaku; Yoshinari Yasuda; Yasuhiro Komatsu; Motoko Yanagita; Yuko Kitagawa; Hiroyuki Kuwano; Hiroyuki Nishiyama; Chikashi Ishioka; Hiromasa Takaishi; Hideki Shimodaira; Akira Mogi; Yuichi Ando; Koji Matsumoto; Daisuke Kadowaki; Satoru Muto
Journal:  Clin Exp Nephrol       Date:  2018-02       Impact factor: 2.801

7.  Measuring the glomerular filtration rate in obese individuals without overt kidney disease.

Authors:  Allon N Friedman; Matthew Strother; Sara K Quinney; Stephen Hall; Susan M Perkins; Edward J Brizendine; Margaret Inman; Gerardo Gomez; Zak Shihabi; Sharon Moe; Lang Li
Journal:  Nephron Clin Pract       Date:  2010-07-02

Review 8.  GFR Measurement and Chemotherapy Dosing in Patients with Kidney Disease and Cancer.

Authors:  Blaithin A McMahon; Mitchell H Rosner
Journal:  Kidney360       Date:  2020-01-13

9.  Population pharmacokinetic meta-analysis of trabectedin (ET-743, Yondelis) in cancer patients.

Authors:  Juan Jose Perez-Ruixo; Peter Zannikos; Sarapee Hirankarn; Kim Stuyckens; Elizabeth A Ludwig; Arturo Soto-Matos; Luis Lopez-Lazaro; Joel S Owen
Journal:  Clin Pharmacokinet       Date:  2007       Impact factor: 6.447

10.  Performance of creatinine-based GFR estimating equations in solid-organ transplant recipients.

Authors:  Kamran Shaffi; Katrin Uhlig; Ronald D Perrone; Robin Ruthazer; Andrew Rule; John C Lieske; Gerjan Navis; Emilio D Poggio; Lesley A Inker; Andrew S Levey
Journal:  Am J Kidney Dis       Date:  2014-04-02       Impact factor: 8.860

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.